HCW Biologics Inc. entered into an Exclusive Distribution Agreement with Akron Biotech on September 4, 2026, for the global commercialization of its product HCW11-006 as a reagent in cell therapy manufacturing, excluding China. The five-year agreement is subject to due diligence and product testing, with closing expected by November 30, 2026. Upon closing, HCW Biologics will receive $400,000 in advance payments: $200,000 at closing, $100,000 within 30 days of a subsequent Supply Agreement execution, and $100,000 on each of the first two anniversaries. Akron will also make quarterly technical support payments. HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia.

HCW Biologics Inc. reported financial results for the quarter ended June 30, 2026, including a net loss of $5.2 million and revenues of $135,568. The company raised approximately $5.6 million in equity financings through private placements in May and July 2026, with participation from executives and directors. HCW Biologics announced preliminary positive data for its lead autoimmune candidate HCW9302 in alopecia areata patients and initiated a Type B meeting with the FDA regarding its T-cell engager candidate HCW11-018b. Additionally, the company re-acquired ex vivo rights to commercial-ready molecules from AlloTera Therapeutics and completed a one-for-six reverse stock split on June 30, 2026. The filing also notes regained compliance with Nasdaq listing rules. HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia.

HCW Biologics Inc. announced on August 10, 2026, that its Audit Committee concluded previously issued unaudited condensed financial statements for the three months ended March 31, 2026, should no longer be relied upon due to a material misstatement in earnings per share (EPS). The error stemmed from an incorrect application of the two-class method for allocating undistributed earnings between common stock and participating warrants. Post-split, reported basic and diluted EPS was $2.19 per share, overstating the correct amount by $0.80 per share because 100% of earnings were allocated to common shares instead of approximately 63.3%. The company identified a material weakness in internal controls regarding technical accounting review for complex warrant instruments. HCW Biologics intends to file an amended Form 10-Q and update related registration statements. The company operates in the biotechnology sector, focusing on the development of biologics.

HCW Biologics Inc. entered into a Securities Purchase Agreement on July 29, 2026, to raise approximately $1.6 million in gross proceeds through the sale of 618,682 units at $2.585 per unit. Each unit consists of one share of common stock or a pre-funded warrant and one common stock purchase warrant exercisable for up to 618,682 shares at an exercise price of $2.585 per share. The issuance of the warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Proceeds will fund clinical development activities, including trials for HCW9302 and IND-enabling studies for HCW11-018b and HCW11-040. The company also entered into a Registration Rights Agreement to file an S-1 within 15 trading days of closing. HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia.

HCW Biologics Inc. reported the settlement and extinguishment of $2.8 million in disputed accounts payable, including a $1.1 million lien satisfaction from B&I Contractors, Inc. and the full payment of a $1.2 million settlement with EirGenix, Inc. regarding manufacturing costs. HCW Biologics Inc. is a biotechnology company focused on the development and manufacturing of biologics.